EUCTR2008-005012-41-IT进行中（未招募）不适用
A multi-center, randomized, double-blind, placebocontrolled clinical trial to evaluate the effect of 52 weeks treatment with vildagliptin on left ventricular function in patients with type 2 diabetes and congestive heart failure - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 246
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must give written informed consent before any assessment is performed. Patients 18-85 years old (inclusive) at Visit 1. Patients with T2DM, diagnosed at least 3 months prior to Visit 1, either untreated (defined as not taking anti-diabetic therapy for at least 8 weeks prior to Visit 1) and maintaining diet and exercise habits during the full course of the study or treated with anti-diabetic therapy (defined as sulfonylurea, insulin, alpha-glucosidase inhibitors, or glinides as monotherapy or combination therapy for at least 8 weeks prior to Visit 1) and maintaining dietary advice and exercise habits during the full course of the study. Stable dose of anti-diabetic therapy over the past 4 weeks prior to Visit 1 (stable insulin therapy is defined as ± 20% of total daily units) for patients on anti-diabetic treatment. CHF (NYHA Class I, Class II, or Class III) at Visit 1. Treatment of heart failure if required should be according to guidelines [ACC/AHA 2005], [ESC/EASD 2007]. LVEF < 40% (results must be available at Visit 2, prior to randomization) HbA1c in the range of > 6.5% to 10% at Visit 1. Body Mass Index (BMI) in the range of 22-42 kg/m2, inclusive, at Visit 1. Male, non-fertile female or female of childbearing potential using a medically approved birth control method. PLS SEE PROTOCOL
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Fasting Plasma Glucose (FPG) ≥ 270 mg/dL (15 mmol/L) at Visit 1. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL). A history of: type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, e.g. Cushing?s syndrome and acromegaly. acute metabolic diabetic complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months. Patients that have been enrolled in a vildagliptin clinical trial or taken part in other DPP-4 inhibitor, GLP-1 mimetics (e.g. exenatide), GLP-1 analogues (e.g. liraglutide) studies within 6 months prior to visit 1. Patients taking vildagliptin at any time.. Patients taking thiazolidinediones (TZDs). TZDs given up to 12 months prior to Visit 1 would be allowed. Acute infections which may affect blood glucose control within 4 weeks prior to visit 1 and other concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study Any of the following within the past 6 months: myocardial infarction (MI) (if the visit 1 ECG reveals patterns consistent with a MI and the date of the event cannot be determined, then the patient can enter the study at the discretion of the investigator and the sponsor); coronary artery bypass surgery or percutaneous coronary intervention unstable angina stroke Any of the following ECG abnormalities: Torsades de pointes, sustained and clinically relevant ventricular tachycardia or ventricular fibrillation second degree AV block (Mobitz 1 and 2); patients with pacemakers are not excluded. PLS SEE PROTOCOL
研究者
相似试验
进行中（未招募）
1 期
A multi-center, randomized, double-blind, placebocontrolled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload - TELESTOmyelodysplastic syndromes(low/int-1 risk)MedDRA version: 12.1Level: LLTClassification code 10019613Term: HemosiderosisEUCTR2009-012418-38-ITOVARTIS FARMA630
进行中（未招募）
不适用
A multi-center, randomized, double-blind, placebocontrolled, two-period cross-over study to assess the effect of 50 µg inhaled NVA237 on exercise endurance in patients with moderate to severe COPD - NDChronic obstructive pulmonary disease (COPD)MedDRA version: 9.1Level: SOCClassification code 10038738EUCTR2010-018597-20-ITOVARTIS FARMA80
招募中
3 期
A multi-center, randomized, double-blind, placebocontrolled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patientsIgA kidney diseaseIgAN10029149NL-OMON56184ovartis3
进行中（未招募）
3 期
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsIgA NephropathyJPRN-jRCT2021200039Yamada Hiroyuki30
招募中
3 期
Coronary computed tomography study to assess the effect of inclisiran on atherosclerotic plaque progression in participants with a diagnosis of nonobstructive coronary artery disease without previous cardiovascular eventsCoronary Artery DiseaseJPRN-jRCT2071230017Hirano Takamitsu5